All lobbying filings

THE KPM GROUP DC LLC

Lobbying for INOZYME PHARMA · Treatments for PPi-Adenosine Pathway, ENPP1 Deficiency, ABCC6 Deficiency, & calciphylaxis.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $20,000.00 income · posted Jul 17, 2025

Official filing document

Bills named in this filing 7

HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025
HR 946
ORPHAN Cures Act
HR 1414
Cameron’s Law
HR 1532
Scientific EXPERT Act of 2025
S 822
Scientific EXPERT Act of 2025
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 1

Pharmacy

H.R.1262/S.932 - Give Kids a Chance Act H.R.946 - ORPHAN Cures Act H.R. 1414 - Cameron's Law H.R.1532/S.822 - Scientific External Process for Educated Review of Therapeutics (EXPERT) Act H.R.1492 - Ensuring Pathways to Innovative Cures (EPIC) Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.